The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.
May 17th 2024
The FDA has approved tarlatamab (Imdelltra; Amgen), a novel bispecific T-cell engager, to treat patients with extensive-stage small cell lung cancer (SCLC).
December 14th 2023
ASCO, ESMO Panel Highlights Progress and Disparities in Lung and Colorectal Cancer Screening
June 22nd 2023A session chaired by ASCO and ESMO leadership included experts on the latest lung and colorectal cancer screening technologies and persistent disparities in screening access and uptake.
Read More
TTFields With SOC Shows Clinically Meaningful Overall Survival Improvement in Metastatic NSCLC
June 16th 2023The phase 3 LUNAR trial evaluating tumor treating fields (TTFields) with standard-of-care therapies met its primary end point in patients with metastatic non–small cell lung cancer (NSCLC).
Read More
Inequalities Within and Between Practices Contribute to NGS Testing Disparities in NSCLC
June 15th 2023A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for patients with advanced non–small cell lung cancer (NSCLC) treated in the community setting.
Read More
ctDNA Tumor Fraction Retains Strong Prognostic Value for Advanced NSCLC
June 9th 2023High circulating tumor DNA (ctDNA) tumor fraction after induction chemotherapy identifies a population with an unmet need who has low chances to benefit from immune checkpoint blockades for non–small cell lung cancer (NSCLC), according to research discussed during a presentation at the American Society of Clinical Oncology Annual Meeting.
Read More
Study Finds Patient Navigation Program Increases Lung Cancer Screening Rates in Urban Setting
June 9th 2023An abstract at the American Society of Clinical Oncology Annual Meeting showed disparities in lung cancer screening rates in an urban, multiethnic community, and patient navigation increased rates overall.
Read More
Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non–Small Cell Lung Cancer
Compared with first-line immunotherapy or chemotherapy alone, combination chemoimmunotherapy for advanced/metastatic non–small cell lung cancer has significantly higher antineoplastic drug and associated medical costs.
Read More
Osimertinib Plus Chemotherapy Improves PFS vs Osimertinib Alone in EGFRm NSCLC
May 17th 2023Osimertinib plus chemotherapy showed a statistically significant improvement in progression-free survival (PFS) vs osimertinib alone in patients with epidermal growth factor receptor–mutated (EGFRm) advanced non–small cell lung cancer (NSCLC)
Read More
Chemotherapy Plus Cemiplimab Improves QOL vs Chemotherapy Alone in NSCLC
May 9th 2023An analysis of the EMPOWER‐Lung 3 trial found that the addition of cemiplimab to platinum chemotherapy for non–small cell lung cancer (NSCLC) was associated with improved patient quality of life (QOL) vs chemotherapy alone.
Read More
Factors Associated With Lung Cancer Risk Factor Documentation
This cross-sectional observational study found several factors associated with whether a patient had sufficient lung cancer risk factor documentation in the electronic health record.
Read More
ASTRO, ESTRO Release First Guideline for Definitive Local Therapy in Oligometastatic NSCLC
April 27th 2023The American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy and Oncology (ESTRO) jointly released a clinical guideline on the use of definitive local therapy for the treatment of oligometastatic non–small cell lung cancer (NSCLC).
Read More
Long-Term Benefits of Cemiplimab Plus Chemotherapy Seen in Locally Advanced NSCLC
April 15th 2023A post-hoc analysis of the EMPOWER-Lung 1 and 3 studies demonstrates long-term survival and responses for patients with locally advanced non–small-cell lung cancer (NSCLC) treated with cemiplimab.
Read More
Sublobar Resection Produces Similar Outcomes to Lobectomy in Early NSCLC
April 5th 2023Patients who underwent sublobar resection and those who underwent more invasive lobectomy for early-stage non–small cell lung cancer (NSCLC) showed similar overall and disease-free survival outcomes in a recent study.
Read More
Dr Davey Daniel on the Importance of Biomarker Tests for Patients With Lung Cancer
April 4th 2023Biomarker testing is a key tool in lung cancer treatment, and Kentucky recently passed a law requiring payers to cover biomarker tests with the intention to address high rates of lung cancer in the state.
Watch
Immunotherapy for NSCLC Safe in Elderly Patients, but More Research Needed
March 30th 2023A review based on an expert panel discussion highlights a need for the inclusion of older patients in studies of immune checkpoint inhibitors for the first-line treatment of advanced non–small cell lung cancer (NSCLC).
Read More